Implications of hormonal contraceptive use for breast cancer risk in BRCA1/2 mutation carriers

In a recent study published in the Journal of Clinical Oncology, Phillips et al. (1) report an observational analysis drawing on four well-annotated cohorts to examine the association between hormonal contraceptive use and breast cancer (BC) risk among BRCA1 and BRCA2 mutation carriers. Given the substantially elevated baseline risk of BC in women with pathogenic BRCA variants, the study addresses a clinically important question with direct implications for contraceptive counselling and reproductive decision-making. The strength of this analysis lies in its scale and follow-up. The authors leverage data from over 5,000 BRCA mutation carriers with detailed exposure histories and longitudinal follow-up approaching six years, enabling robust estimation of risk across multiple dimensions of contraceptive use, including recency, duration, and timing.